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Summary Purpose: To study, in patients on unchanged antiepileptic drugs (AEDs):
(1) seizure rates after 3 and 12 months of vagus nerve stimulation (VNS); (2) effects
of VNS parameters; (3) patient characteristics versus VNS responsiveness. Methods:
We located in the VNS registry 269 patients treated for 1 year with no changes in
AEDs. Seizure rates were calculated at 3 and 12 months. We analyzed: (1) 3 months
versus 12 months seizure rates; (2) effects of changing duty cycles between 3 and 12
months; (3) effects of output current; (4) seizure rate changes associated with patient
characteristics. Results: Seizure rates improved between 3 months (median = −45%)
and 12 months (median = −58%) (P < 0.0001). There were no differences between
patients who stayed on standard or rapid cycling, or changed from standard to rapid.
Stimulation parameters did not affect seizure rates. VNS responsiveness was associ-
ated with older age (P = 0.016), longer duration epilepsy (P = 0.033), and syndromes
other than Lennox—Gastaut (P = 0.003). Conclusions: This was an analysis of treat-
ment outcomes, not a prospective clinical trial. Nonetheless, our results suggest: (1)
seizure rates decline with increasing VNS duration; (2) this decline occurs without
AED changes; (3) this decline is not due to changes in stimulation parameters; (4)
patient characteristics predictive of VNS responsiveness remain elusive.
© 2003 BEA Treading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Most large long-term studies of vagus nerve stim-
ulation (VNS) for intractable epilepsy have found
less seizures with increasing treatment durations,
but those studies allowed concomitant changes in
antiepileptic drugs (AEDs).1—4 In one small study
of 16 children with epileptic encephalopathies, no
changes in AEDs occurred during the ﬁrst year of
VNS; the median seizure rate reduction was 17%.5
However, during the second year of that study,
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AED changes were allowed, and seizures were re-
duced by 43%. It remains unclear if the better
responses seen with longer VNS exposures might
be attributable to changed AEDs rather than to
sustained VNS, or due to a combination of differing
mechanisms of action of VNS and new AEDs. Pre-
viously, we reported that no speciﬁc AED seems to
have unique additive antiseizure effects with VNS.6
Changes in stimulation parameters over time also
may affect outcomes,7 but the long-term effects
of parameter manipulation alone, with unchanged
AEDs, have not been studied.
The VNS treatment outcome registry afforded
us a unique opportunity to identify and study a
large number of patients who received VNS but did
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not change their medical therapy. We were able
to locate a sizable cohort of 269 patients in the
registry who stayed on exactly the same AEDs, at
exactly the same doses, for their entire ﬁrst year of
VNS. Thus, any long-term results reasonably could
be attributed to VNS. This was not a randomized
prospective trial of various stimulation settings.
However, in search of general trends, we divided
our study population into subgroups according to
stimulation parameters employed, and other pa-
tient clinical characteristics, and compared seizure
rate outcomes between these subgroups.
Methods
The VNS patient outcome registry is a database
created by participating prescribing physicians who
voluntarily submit, to a centralized data storage
site, baseline patient clinical information on the
patients they treat, and then submit follow-up in-
formation at various intervals during this therapy.
Baseline data collected about the patients include:
age, epilepsy syndrome (localization-related,
Lennox—Gastaut Syndrome [LGS], or other gen-
eralized), age of epilepsy onset, gender, baseline
seizure rates, baseline AEDs, and history of previ-
ous intracranial epilepsy surgery. Follow-up data
collected 3 and 12 months after VNS implantation
include: seizure frequency, VNS parameters, and
AED type and dose.
We were able to identify 269 patients with 1 year
of VNS treatment who did not change their AED or
their AED dose. No AEDs were added or removed.
We analyzed changes in seizure rates in these 269
patients after 3 and 12 months of VNS therapy,
relative to historical baseline. The relationships
between stimulation parameters, various patient
clinical characteristics, and changes in seizures
rates were studied. Nonparametric statistical anal-
yses were employed when appropriate. Standard
techniques for the surgical implantation of, and
treatment of medication-resistant epilepsy with,
VNS were employed.8—10
Results
Patient demographics
Clinical characteristics of the patient popula-
tion are shown in Table 1. The majority had
localization-related epilepsy (67%). The other third
of patients had LGS or some other form of general-
ized epilepsy. Durations of epilepsy before VNS im-
Table 1 Patient demographics.
Baseline seizure rate/month
(median)
22 (range 0—3300)
Age (median years) 32 (range 2—71)
Epilepsy syndrome
Localization-related (%) 67
Other generalized (%) 24
Lennox—Gastaut (%) 9
Male (n) 136
Female (n) 133
Age at onset (median years) 5 (range 0—47)
Number of AEDs at baseline
(median)
2 (range 1—5)
Patients with history of
prior epilepsy surgery (n)
54
plantation were long (median 22 years) and seizure
rates were high (median 22 seizures/month).
Changes in seizure rates over the ﬁrst year
of VNS therapy
Median seizure rate reduction was 45% after 3
months of VNS (P < 0.0001, Wilcoxon sign-rank
test) and 58% after 12 months (P < 0.0001). This
represents a signiﬁcant improvement between 3
and 12 months (P < 0.0001, Wilcoxon sign-rank
test). The relative frequency of patients with ≥50,
≥75, ≥90, and 100% seizure rate reductions all
increased between 3 and 12 months follow-up
(Fig. 1).
Stimulation parameters and changes in
seizure rates
One explanation for declining seizure rates with
longer VNS exposures might be that higher stimu-
lation settings are achieved with greater follow-up
durations. While treating physicians can adjust var-
ious stimulation parameters (output current, stim-
ulation on-time, stimulation off-time, stimulation
frequency, pulse width), the most commonly mod-
iﬁed parameters are output current and off-time.9
Therefore, we subdivided and analyzed patients’
seizure rate responses according to output currents
and on/off-time (‘‘duty’’) cycles.
Output current
Stimulation currents were classiﬁed as ‘‘low’’
(0.25—1.00mA), ‘‘medium’’ (1.25—2.0mA), or
‘‘high’’ (≥2.25mA). Seizure rate changes at 12
months follow-up for these groups are shown in
Table 2. Patients with high output current exhib-
ited less seizure rate change (median 38% reduc-
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Figure 1 Responder rates after 3 and 12 months of VNS therapy in 269 patients on the same AEDs and same AED
doses.
tion) than those with low (64%) and medium (61%)
output currents (P = 0.0197, Kruskal—Wallis test).
This may indicate that high output currents are less
effective than low and medium currents; that the
high output currents increase the seizure rate in
some cases; or that treating physicians increased
output currents in patients who did not respond
initially to lower settings.
Duty cycle
Seizure rate reductions at 12 months follow-up are
shown for patients with off-times of ≤1.1, 1.8, 3.0,
and ≥5.0min in Table 3. ‘‘Standard’’ (std) cycling
was deﬁned as off-times ≥3.0min; ‘‘rapid’’ (rpd)
cycling was deﬁned as off-times ≤1.8min. There
was no signiﬁcant difference in seizure rate reduc-
tion between standard cycling (median 62%) and
rapid cycling (50%) (P = 0.551, Wilcoxon rank-sum
test).
We further studied the effects of the sequence
of cycling settings at 3 and 12 months on changes
in seizure rates (Table 4). Patients were classiﬁed
as std—std (std at 3 and 12 months), std—rpd (std
at 3 and rpd at 12 months), or rpd—rpd (rpd at 3
and 12 months) (there were only three std—rdp
patients; these three were excluded from compar-
Table 2 VNS output current effects on seizure rates
at 12 months follow-up.
Output
current (mA)
Number of
patients
Median percent
change in seizure
frequency (%)
0.25—1.0 76 −64
1.25—2.0 147 −61
≥2.25 46 −38
isons). The median seizure rates declined between
3 and 12 months follow-up in all three groups; this
decline was signiﬁcant for the std—std (45—63%,
P = 0.0004, Wilcoxon sign-rank test) and rpd—
rpd (67—80%, P = 0.008, Wilcoxon sign-rank test)
groups, and approached signiﬁcance for the std—
rpd group (40—50%, P = 0.092, Wilcoxon sign-rank
test). The seizure rate reduction after 12 months of
VNS therapy was notable in the rpd—rpd subgroup
(median 80%), but the number of patients in this
group was small (n = 21). Upon direct compari-
son, there were no signiﬁcant differences between
the degrees of seizure rate declines from 3 to 12
months when comparing the std—std and rpd—rpd
(P = 0.1198, Wilcoxon rank-sum test) and std—std
and std—rpd (P = 0.3938, Wilcoxon rank-sum test)
groups.
There were 13 patients who were on exactly the
same VNS settings, in addition to being on the ex-
act same AEDs and dosages, at 3 and 12 months
follow-up. Their median seizure rate reduction
was 36% after 3 months, and declined further to
Table 3 VNS duty cycle effects on seizure rates at
12 months follow-up.
Off-time
(min)
Number of
patients
Median percent
change in seizure
frequency (%)
≥5.0 121 −62
3.0 56 −62
1.8 17 −50
≤1.1 75 −55
≥3.0 177 −62
≤1.8 92 −50
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Table 4 Effects of sequential duty cycle changes between 3 and 12 months follow-up on seizure rates.
Duty cycle changes,
3 months vs. 12
months on VNS
Number of
patients
Median percent change
in seizure frequency at
3 months (%)
Median percent change
in seizure frequency at
12 months (%)
Wilcoxon
sign-rank
test P-value
Standard—standard 174 −45 −63 0.0004
Standard—rapid 71 −40 −50 0.092
Rapid—rapid 21 −67 −80 0.008
Table 5 Regression analysis of potential predictors of VNS antiepileptic efﬁcacy.
Variable Value Regression P-values
Age Continuous 0.016
Gender Female vs. male 0.438
Duration Continuous 0.033
Age of epilepsy onset Continuous 0.478
Baseline number of seizure/day Continuous 0.202
Epilepsy syndrome Local vs. general vs. LGS 0.003
Baseline number of AEDs 1—5 0.166
Previous lobectomy No vs. yes 0.554
Previous callosotomy No vs. yes 0.075
85% after 12 months (P = 0.02, Wilcoxon sign-rank
test).
Patient clinical characteristics and changes
in seizure rate
Univariate linear regression models did not reveal
independent signiﬁcant effects of gender, age of
epilepsy onset, baseline seizure rate, number of
baseline AEDs, or history of lobectomy epilepsy
surgery on seizure rate outcomes at 12 months
follow-up (Table 5). Signiﬁcant effects of epilepsy
syndrome (P = 0.003), age (P = 0.016), and dura-
tion of epilepsy (P = 0.033) were observed, and
previous corpus callosotomy approached signiﬁ-
cance (P = 0.075).
Median seizure rate reductions at 12 months
were 37% for LGS patients (n = 22), 55% for patients
with other generalized epilepsies (n = 63), and
65% for patients with localization-related epilepsy
(n = 184). The patients’ median age was 32 years.
The median seizure rate reduction at 12 months
follow-up for patients <32 years old was 50%;
the median seizure rate reduction at 12 months
follow-up for patients ≥32 years was 64%. The
median duration of epilepsy was 22 years. The me-
dian seizure rate reduction at 12 months follow-up
for patients with epilepsy <22 years was 55%; the
median seizure rate reduction at 12 months for
patients with epilepsy for ≥22 years was 64%.
Discussion
Registry methodology
The VNS treatment registry offers some desirable
attributes as a research tool.6 First and foremost
is the large number of patients enrolled by various
treating physicians. We enjoyed the unique circum-
stance of being able to identify and study a very siz-
able cohort of 269 patients on VNS and on exactly
the same AEDs at the same dosages for 1 year. No
previous study has described such a large patient
population in which the only therapeutic maneuver
was the addition of VNS.
However, registries may be subject to patient se-
lection bias. All physicians prescribing VNS do not
participate, and participating physicians may not
register every patient. Thus, registry patients may
not be representative of all patients treated with
VNS.
We attempted to minimize the effects of pa-
tient selection bias by focusing on comparisons
between subgroups within the registry, or between
seizure rate changes at different treatment inter-
vals within our study population. We avoided draw-
ing general conclusions about the expected degree
of VNS treatment efﬁcacy in all treated patients,
since the registry cases may or may not be repre-
sentative of all treated patients. Which patients
are entered into the registry may reﬂect certain
physician behavior trends, and this may bias the
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absolute degree of seizure rate changes we ob-
served. However, such trends should be similarly
operative at 3 and 12 months of VNS treatment,
and most likely would not explain the relative
progressive change in seizure rates over time we
observed in our constant cohort of 269 patients.
Seizure rate changes over time
Studies have shown declining seizure rates with in-
creasing VNS exposure duration.1 In an open-label
extension study of 454 patients exiting pre-
commercial-approval prospective clinical trials,
Morris et al.2 reported median seizure rate re-
ductions of 20% after 3 months of treatment,
35% after 1 year, and 44% after 3 years. The de-
gree of improvement in our study at 1 year was
greater than this. This difference may reﬂect the
post-commercial-approval clinical experience na-
ture of our data.
Previously, there have been no large long-term
studies in which AEDs were held totally constant and
only VNS was added. In our study, not only were no
new AEDs added, but also there were no changes in
doses of baseline AEDs. Therefore, the progressive
seizure rate decline we observedmust be attributed
to VNS alone. It is not likely that this degree of im-
provement occurred spontaneously in these refrac-
tory patients.
Stimulation parameters
We were unable to demonstrate any particular
stimulation parameter characteristics that had ob-
vious greater efﬁcacy than any others. The 46 pa-
tients with output currents ≥2.25mA at 12 months
follow-up did not respond as well as did the other
patients. Caution is in order when assessing the
general signiﬁcance of these results because of the
nature of our research design. Patients were not
randomized to various stimulation settings; physi-
cians chose, changed or continued various settings
on a case-by-case basis based on their medical
judgment and VNS efﬁcacy and tolerability for each
individual patient. These circumstances may have
obscured subtle differences between effectiveness
of various stimulation parameters. For example,
we do not know whether patients who initially
responded well to low stimulation currents, and
remained at those settings, would have improved
even further if their currents had been increased
subsequently. However, in agreement with our
ﬁndings, recently published preliminary results of
a randomized trial of different VNS settings have
failed to suggest any superior stimulation treat-
ment approach.9
Stimulation parameter changes over time
One hypothesis to explain greater average seizure
rate reductions with longer VNS therapy might be
that with longer exposures, more patients achieve
higher stimulation settings (higher currents or duty
cycles changed to rapid cycling), and these are
more effective. Our results do not support this
hypothesis. As noted above, we found increased
current and increased duty cycles were not associ-
ated with greater seizure rate reductions. Further-
more, there was no difference between patients
who stayed on standard cycling and patients who
switched from standard cycling to rapid cycling.
This suggests that accumulating effects of stimula-
tion per se, and not changes in stimulation settings,
lead to late improvement.
Similar to us, in a long-term study of 154
localization-related epilepsy patients on VNS, De-
Giorgio et al.7 found no association between par-
ticular stimulation parameter settings and seizure
rate reductions at 1-year follow-up. They did, how-
ever, report a signiﬁcant reduction in seizure rates
between 3 and 12 months follow-up in patients
who had their stimulation duty cycles changed
from ‘‘standard’’ cycling to off-times ≤1.1min. In
that study the patients who were changed to rapid
cycling by 12 months follow-up were patients who
had experienced only minimal seizure rate reduc-
tions at 3 months. Thus, their ‘‘improvement’’ be-
tween 3 and 12 months only changed their response
from ‘‘less than average’’ to ‘‘average’’. This is
another example of the difﬁculties encountered
when attempting to study treatment efﬁcacy based
on clinical experience rather than on outcomes of
prospective randomized clinical trials.
Predicting responsiveness to VNS
Clinical patient features that reliably predict re-
sponsiveness to VNS therapy have proved elusive. A
summary of the results of previous studies on this
topic is presented in Table 6. This table illustrates
a great lack of consistency between reports; many
features said to be predictive of VNS responsiveness
in one paper were not conﬁrmed as such in other
papers. These reports vary greatly in study designs,
study durations, and patient populations. Some pa-
pers frankly contradict each other. For example,
we found greater duration of epilepsy was associ-
ated with better responsiveness to VNS. This di-
rectly contradicts Refroe and Wheless,18 who using
different methodology, found patients with seizures
for less than 5 years before VNS implantation did
better than patients implanted later in the course
of their illness.
Vagus
nerve
stim
ulation
for
1
year
in
269
patients
on
unchanged
antiepileptic
drugs
397
Table 6 Predictors of responsiveness to VNS: review of the literature.
Predictors of VNS
response
Long
duration of
epilepsy
LGS Older
age
Gender Older age
at epilepsy
onset
Higher
baseline
seizure rate
Prior
lobectomy
Prior corpus
callosotomy
Lower
number of
prior AEDs
Number of
baseline
AEDs
Number of
different
seizure types
Cryptogenic
or idio vs.
symptomatic
Concomitant
AEDs
Abnormal
psychosocial
history
This study + − + o o o o + o
Wernicke et al.11 − +
Hornig et al.12 + +
Tarver13 o o o o + o o o o + +
Labar et al.14 + + o o o
Patwardhan et al.15 o o +
Frost et al.16 o o +
Helmers et al.17 + o − + o
Refroe and Wheless18 − +
Labar6 o
Key: (+) positive correlation with less seizures on VNS; (−) negative correlation with less seizures on VNS; (o) no correlation with seizure rate changes on.
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We found greater seizure rate reductions in pa-
tients older than 32 years compared with younger
patients, whereas Wernicke et al.11 found greater
seizure rate reductions in patients younger than 34
years. Previous separate reports indicate seizure
rates improve similarly in older patients19 and
children.5,12,15—17 Comparing separate indepen-
dent studies (Refs.5,12,15—17 versus Ref.19) is not
equivalent to direct comparisons of different aged
subgroups within a single study population, as we
carried out.
Three earlier reports suggested that patients who
previously underwent corpus callosotomy did well
with VNS;12,16,17 we saw a similar trend in our study.
In summary, however, it appears that, for most pa-
tients, we are as of yet unable to predict whether
seizures will respond to VNS therapy based on their
clinical characteristics.
Conclusions
Our results suggest the following:
1. Seizure rates decline with increasing duration of
VNS therapy.
2. This seizure rate decline can occur without
changes in AEDs.
3. This decline is not due to sequential changes in
stimulation parameters.
4. Similar degrees of long-term seizure rate reduc-
tion are seen on various VNS stimulation settings.
5. Clinical predictors of VNS responsiveness remain
elusive.
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